泽德曼

[References]

This website is intended for healthcare professionals only.

1. Zhao, Yan, Zhu Wei, Yanyan Feng, et al. “Efficacy and Safety of Benvitimod 1% Cream for Atopic Dermatitis in Patients Aged 2 Years and Older: A Phase III Randomized Clinical Trial.” Chinese Medical Journal, ahead of print, September 16, 2025. https://doi.org/10.1097/CM9.0000000000003769.

2. Gold, Linda Stein, James Del Rosso, Benjamin D. Ehst, et al. “Tapinarof Cream 1% Once Daily Was Well Tolerated in Adults and Children with Atopic Dermatitis in Two Phase 3 Randomized Trials.” Journal of Dermatological Treatment 36, no. 1 (2025): 2444489. https://doi.org/10.1080/09546634.2024.2444489.

3. Silverberg, Jonathan I., Lawrence F. Eichenfield, Adelaide A. Hebert, et al. “Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.” Journal of the American Academy of Dermatology 91, no. 3 (2024): 457–65. https://doi.org/10.1016/j.jaad.2024.05.023.

4. Fardos, Mohammad, Nithisha Cheedalla, Austin Raj Watson, and David Esguerra. “Tapinarof in Atopic Dermatitis: A Comprehensive Scoping Review of Clinical Efficacy and Safety.” JAAD Reviews 3 (March 2025): 69–77. https://doi.org/10.1016/j.jdrv.2024.12.001.

5. Zhao, Yan, Chenyu Wu, Lin Cai, et al. “Tapinarof Inhibits Psoriatic Inflammation through Inducing Tolerogenic Dendritic Cells and Foxp3+ Tregs.” Chinese Medical Journal 137, no. 23 (2024): 2877–79. https://doi.org/10.1097/CM9.0000000000003260.

6. Quintana, Francisco J., Alexandre S. Basso, Antonio H. Iglesias, et al. “Control of Treg and TH17 Cell Differentiation by the Aryl Hydrocarbon Receptor.” Nature 453, no. 7191 (2008): 65–71. https://doi.org/10.1038/nature06880

7. Igarashi, Atsuyuki, Gaku Tsuji, Shuichi Fukasawa, Ryusei Murata, and Satoshi Yamane. “Tapinarof Cream for the Treatment of Atopic Dermatitis: Efficacy and Safety Results from Two Japanese Phase 3 Trials.” The Journal of Dermatology 51, no. 11 (2024): 1404–13. https://doi.org/10.1111/1346-8138.17451.

8. Smith, Susan H., Channa Jayawickreme, David J. Rickard, et al. “Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation in Mice and Humans.” Journal of Investigative Dermatology 137, no. 10 (2017): 2110–19. https://doi.org/10.1016/j.jid.2017.05.004.

9. Di Meglio, Paola, João H. Duarte, Helena Ahlfors, et al. “Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions.” Immunity 40, no. 6 (2014): 989–1001. https://doi.org/10.1016/j.immuni.2014.04.019.

10. Van Den Bogaard, Ellen H., Judith G. M. Bergboer, Mieke Vonk-Bergers, et al. “Coal Tar Induces AHR-Dependent Skin Barrier Repair in Atopic Dermatitis.” Journal of Clinical Investigation, January 25, 2013, JCI65642. https://doi.org/10.1172/JCI65642.

11. Chen, Zeyu, Morgan Dragan, Peng Sun, et al. “The AhR-Ovol1-Id1 Regulatory Axis in Keratinocytes Promotes Epidermal and Immune Homeostasis in Atopic Dermatitis-like Skin Inflammation.” Cellular & Molecular Immunology 22, no. 3 (2025): 300–315. https://doi.org/10.1038/s41423-025-01264-z.

12. Jia, Qiuyu, Ping Liu, Xiaojie Wang, et al. “Benvitimod Upregulates Filaggrin, Involucrin and Loricrin Expressions via Aryl Hydrocarbon Receptor-OVO-like 1 Axis.” Archives of Dermatological Research 316, no. 8 (2024): 585. https://doi.org/10.1007/s00403-024-03268-7.

13. Tsuji, Gaku, Akiko Hashimoto-Hachiya, Mari Kiyomatsu-Oda, et al. “Aryl Hydrocarbon Receptor Activation Restores Filaggrin Expression via OVOL1 in Atopic Dermatitis.” Cell Death & Disease 8, no. 7 (2017): e2931–e2931. https://doi.org/10.1038/cddis.2017.322.

14. Wang, Xiaojie, Dandan Mao, Jun Jia, and Jianzhong Zhang. “Benvitimod Inhibits IL-4– and IL-13–Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes.” Journal of Investigative Dermatology 144, no. 3 (2024): 509-519.e7. https://doi.org/10.1016/j.jid.2023.07.027.

15. Polonio, Carolina M., Kimberly A. McHale, David H. Sherr, David Rubenstein, and Francisco J. Quintana. “The Aryl Hydrocarbon Receptor: A Rehabilitated Target for Therapeutic Immune Modulation.” Nature Reviews Drug Discovery, ahead of print, April 17, 2025. https://doi.org/10.1038/s41573-025-01172-x.

16. Silverberg, Jonathan I., Mark Boguniewicz, Francisco J. Quintana, et al. “Tapinarof Validates the Aryl Hydrocarbon Receptor as a Therapeutic Target: A Clinical Review.” Journal of Allergy and Clinical Immunology 154, no. 1 (2024): 1–10. https://doi.org/10.1016/j.jaci.2023.12.013.

17. Diao, Xiaotong, Qinghong Shang, Mengqi Guo, et al. “Structural Basis for the Ligand-Dependent Activation of Heterodimeric AHR-ARNT Complex.” Nature Communications 16, no. 1 (2025): 1282. https://doi.org/10.1038/s41467-025-56574-7.

Marked Improvement in Skin Lesions

Zedman® (Tapinarof Cream) Demonstrated Skin Lesion Improvement and Good Safety in an 8-Week Phase III Randomized Controlled Study

Evaluated in a multicenter Phase III study in China enrolling 271 patients aged ≥2 years with atopic dermatitis.

35 centers; 1% tapinarof cream n=183, placebo n=88; twice daily for 8 weeks.

Marked Improvement in Skin Lesions

In the Pediatric Subgroup (Aged 2–17)

At Week 8, 69.2% of patients achieved EASI75

(Placebo 31.0%)

In the Overall Study Population

Zedman® 54.4% vs Placebo 25.5% (P<0.001)

In the Pediatric Subgroup (Aged 2–17)

At Week 8, 61.5% of patients achieved IGA 0/1 (Clear or Almost Clear)

(Placebo 31.0%)

In the Overall Study Population

Zedman® 46.2% vs Placebo 21.4% (P<0.001)

The most common adverse reactions in patients with atopic dermatitis treated with Zedman® Cream include application site reactions, folliculitis, and contact dermatitis. EASI75: ≥75% improvement in Eczema Area and Severity Index; vIGA-AD: Validated Investigator's Global Assessment for Atopic Dermatitis; IGA-AD efficacy defined as IGA-AD score of 0 (Clear) or 1 (Almost Clear).

Week 8 EASI75: Zedman® vs Placebo

Important Safety Information

Indication: Zedman® (Tapinarof Cream, concentration/strength per package insert)is a drug with an aryl hydrocarbon receptor (AhR)-related mechanism of action. It is indicated for the topical treatment of patients aged 2 years and older.
*Observed adverse events (% placebo-adjusted): application site reactions (7.6%), folliculitis (3.2%), contact dermatitis (0.4%), headache (1.6%).